共 12 条
[1]
In vitro activity of BAY 128039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Souli M,Wennersten CB,Eliopoulous GM. International Journal of Antimicrobial Agents . 1998
[2]
Moxifloxcin versus amoxycillin in the treatment of community-acquired suspected pneumococcal pneumonia: a multinational double-blind randomized study. Petipretz P,Branco PJ,Dosedel J,et al. Clinical Microbiology and Infection . 1995
[3]
Multiple drug-resistant tuberculosis. Bradford WZ,Daley CL. Infectious Diseases in Clinical Practice . 1998
[4]
A review of the clinical pharmacology of moxifloxacin , a new 8methoxyquinolone, and its potential relation to therapeutic efficacy. Wise R. Clin Drug Inves . 1999
[5]
Dose appropriate antibiotic treatment influence outcome in community-acquired pneumonia(CAP). Niederman M,Church D,Kaufmann J,et al. Respiratory Medicine . 2000
[6]
In vitro activity of BAY 12-8039, a new fluoroquinolone. Woodcock JM,Andrews JM,Boswell JF,et al. Antimicrobial Agents and Chemotherapy . 1997
[7]
Concentration-dependent killing of antibioticresistant pneumococci by the methoxyquinolone moxifloxacin. Klugman KP,Capper T. Journal of Antimicrobial Chemotherapy . 1997
[8]
Fluoroquinolonesafetyandtolerability. BallP. Proceedingoffirstinternationalmoxifloxacinsymposium . 1999
[9]
Study to evaluate the interaction between moxifloxacin ( M ) and iron supplements ( FE ). Stass HH,Kubitza D. Antiinfect Drug Chemother . 1998
[10]
Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams. Visalli MA,Jacobs MR,Appelbaum PC. Antimicrobial Agents and Chemotherapy . 1997